CERE vs. MLTX, FOLD, IMGN, INSM, AXSM, CORT, CYTK, EVO, MDGL, and BPMC
Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include MoonLake Immunotherapeutics (MLTX), Amicus Therapeutics (FOLD), ImmunoGen (IMGN), Insmed (INSM), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), Cytokinetics (CYTK), Evotec (EVO), Madrigal Pharmaceuticals (MDGL), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Cerevel Therapeutics vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
MoonLake Immunotherapeutics has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.
MoonLake Immunotherapeutics presently has a consensus price target of $58.80, suggesting a potential upside of 10.57%. Cerevel Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 64.81%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe Cerevel Therapeutics is more favorable than MoonLake Immunotherapeutics.
87.7% of Cerevel Therapeutics shares are owned by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cerevel Therapeutics' return on equity of -23.18% beat MoonLake Immunotherapeutics' return on equity.
Cerevel Therapeutics received 129 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. Likewise, 68.61% of users gave Cerevel Therapeutics an outperform vote while only 64.86% of users gave MoonLake Immunotherapeutics an outperform vote.
In the previous week, MoonLake Immunotherapeutics had 9 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 10 mentions for MoonLake Immunotherapeutics and 1 mentions for Cerevel Therapeutics. Cerevel Therapeutics' average media sentiment score of -0.15 beat MoonLake Immunotherapeutics' score of -1.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Cerevel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
MoonLake Immunotherapeutics beats Cerevel Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Cerevel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cerevel Therapeutics Competitors List
Related Companies and Tools